Aurobindo Pharma Subsidiary Eugia Gets 4 US FDA Observations for Shameerpet Unit

Aurobindo Pharma Limited reported that the United States Food and Drug Administration issued four observations following an inspection at a facility belonging to its wholly owned subsidiary, Eugia Pharma Specialities Ltd.

According to a filing submitted to the NSE and BSE, the inspection was conducted at Unit-I, a formulation manufacturing facility located at Kolthur Village, Shameerpet Mandal in  Telangana.

US FDA officials carried out the review from Feb 16-27, 2026 which concluded with 4 observations. The company stated it would respond to the US FDA within the stipulated timelines.

Aurobindo Pharma clarified the potential implications will have no impact on the Company’s financials or operations due to the said action.